Payment overview · 2025
General Payments
$514.37
22 reported records · 8 companies
Healthcare provider profile · identity verified
Brittany Vanraaphorst
Allopathic & Osteopathic Physicians|Family Medicine · ENGLEWOOD, FL · NPI 1871980680
Verified facts
What the public records show
CMS Open Payments records show Brittany Vanraaphorst received $514.37 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.98 | 37.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.90 | 22.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $95.17 | 18.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.91 | 5.6% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $23.65 | 4.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.07 | 4.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.89 | 4.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.80 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $514.37 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $190.98 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.00 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $80.54 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.54 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.89 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 579 | 189 |
| Lisinopril | Lisinopril | 310 | 108 |
| Losartan Potassium | Losartan Potassium | 300 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 89 |
| Alprazolam | Alprazolam | 275 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 90 |
| Metformin Hcl | Metformin Hcl | 219 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 59 |
| Omeprazole | Omeprazole | 205 | 70 |
| Trazodone Hcl | Trazodone Hcl | 179 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 51 |
| Gabapentin | Gabapentin | 154 | 52 |
| Simvastatin | Simvastatin | 153 | 46 |
| Sertraline Hcl | Sertraline Hcl | 129 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 37 |
| Montelukast Sodium | Montelukast Sodium | 116 | 44 |
| Baclofen | Baclofen | 107 | 51 |
| Prednisone | Prednisone | 106 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 30 |
| Bupropion Xl | Bupropion Hcl | 99 | 36 |
| Meloxicam | Meloxicam | 97 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 23 |
| Allopurinol | Allopurinol | 85 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 30 |
| Atenolol | Atenolol | 76 | 22 |
| Tramadol Hcl | Tramadol Hcl | 76 | 26 |
| Furosemide | Furosemide | 75 | 28 |
| Ozempic | Semaglutide | 74 | 18 |
| Topiramate | Topiramate | 74 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 63 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 25 |
| Lorazepam | Lorazepam | 68 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 55 |
| Metformin Hcl Er | Metformin Hcl | 62 | 22 |
| Azithromycin | Azithromycin | 61 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 23 |
| Clonazepam | Clonazepam | 56 | 17 |
| Potassium Chloride | Potassium Chloride | 56 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 15 |
| Celecoxib | Celecoxib | 52 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 20 |
| Estradiol | Estradiol | 51 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Famotidine | Famotidine | 50 | 20 |
| Ondansetron Odt | Ondansetron | 49 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Carvedilol | Carvedilol | 48 | 15 |
| Temazepam | Temazepam | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 14 |
| Eliquis | Apixaban | 44 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 16 |
| Synthroid | Levothyroxine Sodium | 44 | 13 |
| Valsartan | Valsartan | 41 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 19 |
| Fenofibrate | Fenofibrate | 38 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 20 |
| Buspirone Hcl | Buspirone Hcl | 35 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 33 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 13 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 22 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Nystatin | Nystatin | 25 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Folic Acid | Folic Acid | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Metronidazole | Metronidazole | 20 | 12 |
| Primidone | Primidone | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Progesterone | Progesterone, Micronized | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $514.37 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, EVENITY, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, UBRELVY, Veozah, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error